Anti-MrkA Monoclonal Antibodies Reveal Distinct Structural and Antigenic Features of MrkA

• Published in: PloS one 2017-01, Vol.12 (1), p.e0170529-e0170529
• Main Authors: Wang, Qun, Chen, Yan, Cvitkovic, Romana, Pennini, Meghan E, Chang, Chew Shun, Pelletier, Mark, Bonnell, Jessica, Koksal, Adem C, Wu, Herren, Dall'Acqua, William F, Stover, C Kendall, Xiao, Xiaodong
• Format: Article
• Language: English
• Subjects: Animals; Antibiotics; Antibodies, Bacterial - immunology; Antibodies, Monoclonal - immunology; Antigens; Antigens, Bacterial - immunology; Biofilms; Biology and Life Sciences; Dosage and administration; Drug resistance; Drug Resistance, Multiple, Bacterial - immunology; Drug therapy; Engineering; Epitopes; Epitopes - immunology; Flow Cytometry; Genetic aspects; Immunoglobulins; Immunotherapy; Infectious diseases; Interferometry; Klebsiella; Klebsiella infections; Klebsiella Infections - immunology; Klebsiella pneumoniae; Klebsiella pneumoniae - immunology; Labeling; Laboratory animals; Libraries; Medicine and Health Sciences; Mice; Mice, Inbred C57BL; Microbial drug resistance; Monoclonal antibodies; Multidrug resistance; Nosocomial infections; Panning; Pathogenesis; Phage display; Phages; Proteins; Recombinant Proteins; Research and Analysis Methods; Target recognition; Vaccines
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0170529

Antibody therapy against antibiotics resistant Klebsiella pneumoniae infections represents a promising strategy, the success of which depends critically on the ability to identify appropriate antibody targets. Using a target-agnostic strategy, we recently discovered MrkA as a potential antibody target and vaccine antigen. Interestingly, the anti-MrkA monoclonal antibodies isolated through phage display and hybridoma platforms all recognize an overlapping epitope, which opens up important questions including whether monoclonal antibodies targeting different MrkA epitopes can be generated and if they possess different protective profiles. In this study we generated four anti-MrkA antibodies targeting different epitopes through phage library panning against recombinant MrkA protein. These anti-MrkA antibodies elicited strong in vitro and in vivo protections against a multi-drug resistant Klebsiella pneumoniae strain. Furthermore, mutational and epitope analysis suggest that the two cysteine residues may play essential roles in maintaining a MrkA structure that is highly compacted and exposes limited antibody binding/neutralizing epitopes. These results suggest the need for further in-depth understandings of the structure of MrkA, the role of MrkA in the pathogenesis of Klebsiella pneumoniae and the protective mechanism adopted by anti-MrkA antibodies to fully explore the potential of MrkA as an efficient therapeutic target and vaccine antigen.